Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Inje University, Korea.
Br J Clin Pharmacol. 2010 Aug;70(2):213-21. doi: 10.1111/j.1365-2125.2010.03688.x.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * CYP2C9 single nucleotide polymorphisms (SNPs) are important in safe and effective oral anticoagulation with warfarin use. * Although CYP2C9*2 and 3 are important genetic factors for the warfarin dose, one of the CYP2C9 SNPs, IVS-65G>C, has been suggested to be associated with warfarin sensitivity. However, as of yet, there has been no explanation about the possible mechanism and linkage analysis. WHAT THIS PAPER ADDS * New information on CYP2C9 SNPs and their occurrences in common haplotype structures in healthy unrelated Koreans and in individuals who require low warfarin dose after mechanical heart valve replacements (MHVRs) were studied. * Additional evidence showed that an Asian dominant haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G and IVS5-73A>G could be associated with a low warfarin maintenance dose in mechanical heart valve replacement (MHVR) patients. AIMS The objectives of this study were to determine the distribution of CYP2C9 variants in Koreans and investigate their association with warfarin dose requirements in patients who received MHVRs. METHODS All nine exons, intron-exon junction, and promoter region of CYP2C9 were amplified and directly sequenced in 50 healthy normal Koreans. Additional direct DNA sequencing of the CYP2C9 gene was conducted in 36 of the 267 MHVR patients who required low maintenance warfarin doses without carrying CYP2C93 and VKORC1 1173T mutations. The effects of CYP2C9 genetics on warfarin maintenance dose were assessed in 267 MHVR patients. RESULTS Thirty-nine single nucleotide polymorphisms (SNPs) including seven previously unidentified SNPs were identified in 50 Koreans by direct DNA sequencing. One of the CYP2C9 haplotypes exhibited an association with warfarin low dose requirement. The adjusted odds ratio for the haplotype between the low dose group and the normal subjects was 2.5 (95% confidence interval 1.05, 6.16). This haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G was found in 15% of 36 MHVR patients who required low warfarin doses, while 4% of 50 normal healthy subjects exhibited this haplotype. One of the SNPs comprising this haplotype, -1565C>T, apparently changed a protein binding pattern as observed in electrophoretic mobility shift assay. CONCLUSION The haplotype including -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G seems to be associated with low warfarin dose requirement and this haplotype could be considered in the development of a warfarin dose prediction model for Asian populations.
CYP2C9 单核苷酸多态性(SNP)在华法林使用的安全有效抗凝治疗中非常重要。
虽然 CYP2C9*2 和 *3 是华法林剂量的重要遗传因素,但CYP2C9 中的一个 SNP,即 IVS-65G>C,被认为与华法林敏感性有关。然而,到目前为止,还没有关于可能的机制和连锁分析的解释。
研究了健康无关的韩国人群中 CYP2C9 SNPs 及其常见单倍型结构的发生情况,以及机械心脏瓣膜置换(MHVR)后需要低华法林维持剂量的个体。
额外的证据表明,一个亚洲优势单倍型,由-1565C>T、-1188T>C、IVS3+197G>A、IVS3-334C>T、IVS3-65G>C、IVS4-115A>G 和 IVS5-73A>G 组成,可能与机械心脏瓣膜置换(MHVR)患者的低华法林维持剂量有关。
本研究的目的是确定 CYP2C9 变体在韩国人群中的分布,并研究其与接受 MHVR 患者华法林剂量需求的关系。
在 50 名健康的韩国人中,我们扩增并直接测序了 CYP2C9 的所有九个外显子、内含子-外显子交界处和启动子区域。对 267 名 MHVR 患者中的 36 名患者进行了 CYP2C9 基因的额外直接 DNA 测序,这些患者在不携带 CYP2C9*3 和 VKORC1 1173T 突变的情况下,需要低维持华法林剂量。评估了 CYP2C9 遗传因素对 267 名 MHVR 患者华法林维持剂量的影响。
通过直接 DNA 测序,在 50 名韩国人中发现了 39 个单核苷酸多态性(SNP),包括 7 个以前未识别的 SNP。CYP2C9 单倍型之一与低剂量华法林需求有关。低剂量组与正常组之间该单倍型的调整比值比为 2.5(95%置信区间 1.05,6.16)。由-1565C>T、-1188T>C、IVS3+197G>A、IVS3-334C>T、IVS3-65G>C、IVS4-115A>G 和 IVS5-73A>G 组成的单倍型在需要低华法林剂量的 36 名 MHVR 患者中占 15%,而在 50 名正常健康受试者中占 4%。该单倍型中的一个 SNP,-1565C>T,显然改变了电泳迁移率变动分析中观察到的蛋白质结合模式。
包括-1565C>T、-1188T>C、IVS3+197G>A、IVS3-334C>T、IVS3-65G>C、IVS4-115A>G 和 IVS5-73A>G 的单倍型似乎与低华法林剂量需求有关,该单倍型可以在亚洲人群的华法林剂量预测模型的开发中加以考虑。